Boris L Gala-Lopez1,2, Daniel Neiman3, Tatsuya Kin1, Doug O'Gorman1, Andrew R Pepper1, Andrew J Malcolm3, Sheina Pianzin3, Peter A Senior4, Patricia Campbell4, Benjamin Glaser5, Yuval Dor3, Ruth Shemer3, A M James Shapiro1,4,2. 1. Department of Surgery and Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada. 2. Canadian National Transplant Research Program (CNTRP). 3. Department of Developmental Biology and Cancer Research, The Hebrew University-Hadassah Medical School, Jerusalem, Israel. 4. Department of Medicine and Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada. 5. Endocrinology and Metabolism Service, Department of Internal Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Abstract
BACKGROUND: Optimizing engraftment and early survival after clinical islet transplantation is critical to long-term function, but there are no reliable, quantifiable measures to assess beta cell death. Circulating cell-free DNA (cfDNA) derived from beta cells has been identified as a novel biomarker to detect cell loss and was recently validated in new-onset type 1 diabetes and in islet transplant patients. METHODS: Herein we report beta cell cfDNA measurements after allotransplantation in 37 subjects and the correlation with clinical outcomes. RESULTS: A distinctive peak of cfDNA was observed 1 hour after transplantation in 31 (83.8%) of 37 subjects. The presence and magnitude of this signal did not correlate with transplant outcome. The 1-hour signal represents dead beta cells carried over into the recipient after islet isolation and culture, combined with acute cell death post infusion. Beta cell cfDNA was also detected 24 hours posttransplant (8/37 subjects, 21.6%). This signal was associated with higher 1-month insulin requirements (P = 0.04), lower 1-month stimulated C-peptide levels (P = 0.01), and overall worse 3-month engraftment, by insulin independence (receiver operating characteristic-area under the curve = 0.70, P = 0.03) and beta 2 score (receiver operating characteristic-area under the curve = 0.77, P = 0.006). CONCLUSIONS: cfDNA-based estimation of beta cell death 24 hours after islet allotransplantation correlates with clinical outcome and could predict early engraftment.
BACKGROUND: Optimizing engraftment and early survival after clinical islet transplantation is critical to long-term function, but there are no reliable, quantifiable measures to assess beta cell death. Circulating cell-free DNA (cfDNA) derived from beta cells has been identified as a novel biomarker to detect cell loss and was recently validated in new-onset type 1 diabetes and in islet transplant patients. METHODS: Herein we report beta cell cfDNA measurements after allotransplantation in 37 subjects and the correlation with clinical outcomes. RESULTS: A distinctive peak of cfDNA was observed 1 hour after transplantation in 31 (83.8%) of 37 subjects. The presence and magnitude of this signal did not correlate with transplant outcome. The 1-hour signal represents dead beta cells carried over into the recipient after islet isolation and culture, combined with acute cell death post infusion. Beta cell cfDNA was also detected 24 hours posttransplant (8/37 subjects, 21.6%). This signal was associated with higher 1-month insulin requirements (P = 0.04), lower 1-month stimulated C-peptide levels (P = 0.01), and overall worse 3-month engraftment, by insulin independence (receiver operating characteristic-area under the curve = 0.70, P = 0.03) and beta 2 score (receiver operating characteristic-area under the curve = 0.77, P = 0.006). CONCLUSIONS: cfDNA-based estimation of beta cell death 24 hours after islet allotransplantation correlates with clinical outcome and could predict early engraftment.
Authors: Emily K Sims; Carmella Evans-Molina; Sarah A Tersey; Decio L Eizirik; Raghavendra G Mirmira Journal: Diabetologia Date: 2018-08-15 Impact factor: 10.122
Authors: Daniel Neiman; David Gillis; Sheina Piyanzin; Daniel Cohen; Ori Fridlich; Joshua Moss; Aviad Zick; Tal Oron; Frida Sundberg; Gun Forsander; Oskar Skog; Olle Korsgren; Floris Levy-Khademi; Dan Arbel; Saar Hashavia; A M James Shapiro; Cate Speake; Carla Greenbaum; Jennifer Hosford; Amanda Posgai; Mark A Atkinson; Benjamin Glaser; Desmond A Schatz; Ruth Shemer; Yuval Dor Journal: JCI Insight Date: 2020-07-23
Authors: Casey Ward; Jon S Odorico; Michael R Rickels; Thierry Berney; George W Burke; Thomas W H Kay; Olivier Thaunat; Pablo D Uva; Eelco J P de Koning; Helmut Arbogast; Hanne Scholz; Mark S Cattral; Robert J Stratta; Peter G Stock Journal: Transplantation Date: 2022-07-22 Impact factor: 5.385
Authors: Salamah M Alwahsh; Omar Qutachi; Philip J Starkey Lewis; Andrew Bond; June Noble; Paul Burgoyne; Nik Morton; Rod Carter; Janet Mann; Sofia Ferreira-Gonzalez; Marta Alvarez-Paino; Stuart J Forbes; Kevin M Shakesheff; Shareen Forbes Journal: Am J Transplant Date: 2021-02-02 Impact factor: 9.369
Authors: Joshua Moss; Judith Magenheim; Daniel Neiman; Hai Zemmour; Netanel Loyfer; Amit Korach; Yaacov Samet; Myriam Maoz; Henrik Druid; Peter Arner; Keng-Yeh Fu; Endre Kiss; Kirsty L Spalding; Giora Landesberg; Aviad Zick; Albert Grinshpun; A M James Shapiro; Markus Grompe; Avigail Dreazan Wittenberg; Benjamin Glaser; Ruth Shemer; Tommy Kaplan; Yuval Dor Journal: Nat Commun Date: 2018-11-29 Impact factor: 14.919
Authors: Martha Lappas; Harry M Georgiou; Jane C Willcox; Michael Permezel; Alexis Shub; Cody-Lee Maynard; Mugdha V Joglekar; Anandwardhan A Hardikar Journal: J Diabetes Res Date: 2019-07-24 Impact factor: 4.011